In a patient with chronic sleep‑maintenance insomnia who has failed multiple pharmacologic trials and is currently taking suvorexant (Belsomra) 15 mg nightly plus trazodone 75 mg nightly without improvement, what are the next management steps?

Discontinue trazodone and initiate cognitive behavioral therapy for insomnia (CBT-I) as the priority intervention, with consideration of low-dose doxepin (3-6 mg) or eszopiclone (2-3 mg) as pharmacologic adjuncts if CBT-I alone is insufficient.

Rationale for Discontinuing Current Regimen

Your patient has failed the current combination of suvorexant 15 mg and trazodone 75 mg, and trazodone specifically should be discontinued. The 2017 AASM guideline explicitly recommends against using trazodone for sleep maintenance insomnia 1. This recommendation is based on insufficient efficacy data, and recent meta-analyses confirm trazodone does not significantly improve subjective total sleep time 2. The FDA label for suvorexant indicates maximum dosing is 20 mg 3, but given her extensive prior failure with suvorexant at 5 mg, simply increasing the dose is unlikely to provide meaningful benefit.

Primary Treatment Recommendation: CBT-I

The American College of Physicians (2016) provides a strong recommendation that all adult patients receive CBT-I as initial treatment for chronic insomnia disorder 4. Even though your patient has been on medications for years, CBT-I remains the gold standard and should be implemented now. The 2008 AASM guideline emphasizes that psychological/behavioral interventions are effective for chronic insomnia and should be utilized as initial intervention when conditions permit 5.

Key components to implement:

• Stimulus control therapy: Bed only for sleep/sex, leave bed if awake >20 minutes, consistent wake time
• Sleep restriction therapy: Limit time in bed to actual sleep time plus 30 minutes, gradually increase
• Cognitive therapy: Address maladaptive beliefs about sleep
• Relaxation techniques: Progressive muscle relaxation or guided imagery

The VA/DOD 2020 guideline suggests CBT-I over pharmacotherapy as first-line treatment even in treatment-refractory cases 6.

Pharmacologic Options if CBT-I Alone Insufficient

Given her sleep-maintenance insomnia pattern (repeatedly waking and staying awake), the following evidence-based sequence should be considered:

First-Line Pharmacologic Option: Low-Dose Doxepin

Low-dose doxepin (3-6 mg) is specifically recommended for sleep maintenance insomnia 1. The 2017 AASM guideline suggests clinicians use doxepin as treatment for sleep maintenance insomnia in adults. This is a weak recommendation but based on actual efficacy data, unlike trazodone. Doxepin works through H1 histamine receptor antagonism at low doses without significant anticholinergic effects at 3-6 mg dosing.

Critical prescribing details:

• Start at 3 mg nightly, 30 minutes before bed
• Can increase to 6 mg if 3 mg insufficient after 1-2 weeks
• Do not exceed 6 mg (higher doses increase anticholinergic burden)
• Monitor for next-day somnolence, though less common at low doses

Second-Line Pharmacologic Option: Eszopiclone

Eszopiclone 2-3 mg is recommended for both sleep onset and sleep maintenance insomnia 1. Given her extensive prior trials, eszopiclone represents a benzodiazepine receptor agonist (BzRA) she has not yet tried. The 2008 guideline recommends trying alternate BzRAs if initial agents unsuccessful 5.

Critical prescribing details:

• Start at 2 mg nightly immediately before bed
• Can increase to 3 mg if 2 mg insufficient after 1 week
• Common adverse effect: dysgeusia (metallic taste) - warn patient
• Monitor for next-day somnolence

Third-Line Option: Temazepam

Temazepam 15 mg is suggested for sleep onset and maintenance insomnia 1. This represents a benzodiazepine option she has not tried. However, the VA/DOD guideline (2020) suggests against benzodiazepines for chronic insomnia due to dependence risk 6, so this should be reserved for cases where non-benzodiazepine options have failed.

What NOT to Do

Do not:

• Continue trazodone at any dose - explicitly not recommended 1
• Increase suvorexant to 20 mg alone - she already failed lower doses
• Try ramelteon - she already failed this at 8 mg
• Use quetiapine - she had panic attack with 15 mg previously
• Use triazolam - she already failed 0.25 mg
• Use zaleplon - she already failed 5 mg
• Use zolpidem - she tried this years ago without benefit
• Use OTC antihistamines - not recommended for chronic insomnia 5, 1
• Use melatonin - not recommended, insufficient evidence 1

Addressing Mood Impact

Her description of feeling "grumpy," not wanting to be around people, and stating she "can't deal with them" suggests mood dysregulation secondary to chronic sleep deprivation. Screen for major depressive disorder using PHQ-9. If depression is present, this becomes comorbid insomnia, and the 2008 guideline notes sedating antidepressants may be appropriate when treating comorbid depression/anxiety 5. However, if depression is present, consider mirtazapine 7.5-15 mg (not trazodone) as it addresses both conditions, though this is off-label for insomnia.

Practical Implementation Algorithm

Week 1-2:

1. Discontinue trazodone 75 mg
2. Continue suvorexant 15 mg temporarily for stability
3. Initiate CBT-I referral (sleep psychologist, behavioral sleep medicine specialist, or digital CBT-I program)
4. Begin sleep diary

Week 3-4:

1. Assess CBT-I engagement and early response
2. If inadequate response, add low-dose doxepin 3 mg
3. Begin tapering suvorexant (reduce to 10 mg for 1 week, then 5 mg for 1 week, then discontinue)

Week 6-8:

1. If doxepin 3 mg insufficient, increase to 6 mg
2. Continue CBT-I
3. Reassess sleep diary data

Week 10-12:

1. If doxepin 6 mg + CBT-I insufficient, consider switching to eszopiclone 2 mg
2. Taper doxepin over 1 week while starting eszopiclone

Critical Monitoring

• Sleep diary: Track nightly to assess objective changes in sleep maintenance
• Daytime functioning: Monitor mood, irritability, social withdrawal
• Adverse effects: Somnolence, falls risk, cognitive impairment
• Follow-up schedule: Every 2-4 weeks initially per guideline recommendations 5

Common Pitfalls to Avoid

1. Polypharmacy trap: She's currently on two sleep medications - this violates the principle of using lowest effective dose 5
2. Ignoring CBT-I: Medications alone have failed repeatedly; behavioral intervention is essential 4
3. Dose escalation without reassessment: The 2008 guideline emphasizes efforts to employ lowest effective maintenance dosage 5
4. Missing underlying sleep disorders: Consider polysomnography if treatment-refractory to rule out sleep apnea, periodic limb movements, or other primary sleep disorders 5

The evidence strongly supports that continuing her current failed regimen or simply adjusting doses will not improve outcomes. A fundamental shift to CBT-I with evidence-based pharmacologic support (doxepin or eszopiclone, not trazodone) offers the best chance for meaningful improvement in both sleep and quality of life.